Application No. 10/537,319 Docket No.: 20489/0202976-US0 Reply to Office Action of November 22, 2006

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) <u>A method for inhibiting angiogenesis, the method comprising administering An inhibitor of angiogenesis containing to a subject in need thereof, an effective amount of tetraacetylphytosphingosine.</u>

- 2. (Currently Amended) A kit for treating cancer <u>or inhibiting angiogenesis</u>, comprising an inhibitor of angiogenesis containing tetraacetylphytosphingosine<u>the</u> for treating cancer or inhibiting <u>angiogenesis</u>.
- 3. (Currently Amended) The kit for treating cancer <u>or inhibiting angiogenesis</u> according to claim 2, wherein further comprising <u>an</u> anti-cancer drug and <u>an</u> irradiator.
- 4. (Currently Amended) The kit for treating cancer <u>or inhibiting angiogenesis</u> according to claim 3, wherein the anti-cancer drug is <u>comprises</u> at least <u>one</u> spingolipid derivatives.
- 5. (Currently Amended) The kit for treating cancer <u>or inhibiting angiogenesis</u> according to claim 4, wherein the spingolipid derivatives <u>comprise are</u> one or more spingolipid derivatives selected from the group consisting of phytosphingosine, <u>enacethylphytosphingosine</u> <u>Nacetylphytosphingosine</u>, C6 phytoceramide, C8 phytosphingosine, dimethylphytosphingosine, dimethylphytosphingosine and sphingosine. <u>A composition for inhibiting the activity of tyrosinase</u> which comprises Nacetylphytosphingosine as an active ingredient.
- 6. (New) A method for treating cancer, the method comprising administering to a subject in need thereof, an effective amount of tetraacetylphytosphingosine.